Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Newspaper Article
|
![]() |
Komodo Health Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024Business Wire, 2024-05-06COPYRIGHT 2024 Business Wire, Inc.Digital Resources/Online E-Resources |
2 |
Material Type: Newspaper Article
|
![]() |
John Hopkin's University Publishes Efficacy of QuadraMune Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory StudiesBusiness Wire, 2022-05-27COPYRIGHT 2022 Business Wire, Inc.Digital Resources/Online E-Resources |
3 |
Material Type: Newspaper Article
|
![]() |
Fractyl Health Demonstrated Significant Improvement in Weight Loss in Head-to-Head Preclinical Obesity Studies of its Rejuva GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Compared to Chronic Semaglutide at EASD's Annual MeetingBusiness Wire, 2023-10-04COPYRIGHT 2023 Business Wire, Inc.Digital Resources/Online E-Resources |
4 |
Material Type: Newspaper Article
|
![]() |
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studiesBusiness Wire, 2022-03-21COPYRIGHT 2022 Business Wire, Inc.Digital Resources/Online E-Resources |
5 |
Material Type: Newspaper Article
|
![]() |
Laboratory Studies Confirm BETADINE Antiseptic Products' Effectiveness Against COVID-19 VirusBusiness Wire, 2020-07-09COPYRIGHT 2020 Business Wire, Inc.Digital Resources/Online E-Resources |
6 |
Material Type: Newspaper Article
|
![]() |
Laboratory Studies Confirm the Effectiveness of BETADINE Gargle and Mouthwash Against COVID-19 VirusBusiness Wire, 2020-06-30COPYRIGHT 2020 Business Wire, Inc.Digital Resources/Online E-Resources |
7 |
Material Type: Newspaper Article
|
![]() |
Fractyl Health Demonstrates Significant Improvement in Glucose Control and Obesity in Preclinical Studies of its Rejuva GLP-1 Based Pancreatic Gene Therapy (GLP1 PGTx) Compared to Chronic Semaglutide at ADA's 83rd Scientific SessionsBusiness Wire, 2023-06-24COPYRIGHT 2023 Business Wire, Inc.Digital Resources/Online E-Resources |
8 |
Material Type: Newspaper Article
|
![]() |
New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2Business Wire, 2020-11-30COPYRIGHT 2020 Business Wire, Inc.Digital Resources/Online E-Resources |
9 |
Material Type: Newspaper Article
|
![]() |
Immunicom Presents Promising Preliminary Data from Immunopheresis Studies in Late-Stage Cancer Patients at JCA-AACR 2021Business Wire, 2021-09-14COPYRIGHT 2021 Business Wire, Inc.Digital Resources/Online E-Resources |
10 |
Material Type: Newspaper Article
|
![]() |
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting in the USBusiness Wire, 2024-05-09COPYRIGHT 2024 Business Wire, Inc.Digital Resources/Online E-Resources |
11 |
Material Type: Newspaper Article
|
![]() |
Swing Therapeutics Announces Positive Results from Studies of Stanza, a Digital Therapeutic for Fibromyalgia TreatmentBusiness Wire, 2022-11-21COPYRIGHT 2022 Business Wire, Inc.Digital Resources/Online E-Resources |
12 |
Material Type: Newspaper Article
|
![]() |
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual MeetingBusiness Wire, 2022-05-24COPYRIGHT 2022 Business Wire, Inc.Digital Resources/Online E-Resources |
13 |
Material Type: Newspaper Article
|
![]() |
Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 StudiesBusiness Wire, 2019-03-18COPYRIGHT 2019 Business Wire, Inc.Digital Resources/Online E-Resources |
14 |
Material Type: Newspaper Article
|
![]() |
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant AscitesBusiness Wire, 2022-05-23COPYRIGHT 2022 Business Wire, Inc.Digital Resources/Online E-Resources |
15 |
Material Type: Newspaper Article
|
![]() |
Published Research Shows Initial Results from SARS-CoV-2 Surveillance Studies Support U.S. Public Health InitiativesBusiness Wire, 2022-04-27COPYRIGHT 2022 Business Wire, Inc.Digital Resources/Online E-Resources |
16 |
Material Type: Newspaper Article
|
![]() |
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology Infectious Diseases (ECCMID)Business Wire, 2021-07-12COPYRIGHT 2021 Business Wire, Inc.Digital Resources/Online E-Resources |
17 |
Material Type: Newspaper Article
|
![]() |
Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas' Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike VaccineBusiness Wire, 2021-06-02COPYRIGHT 2021 Business Wire, Inc.Digital Resources/Online E-Resources |
18 |
Material Type: Newspaper Article
|
![]() |
New Studies Highlight Activity of XERAVA Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant PathogensBusiness Wire, 2019-06-24COPYRIGHT 2019 Business Wire, Inc.Digital Resources/Online E-Resources |
19 |
Material Type: Newspaper Article
|
![]() |
bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)Business Wire, 2021-02-16COPYRIGHT 2021 Business Wire, Inc.Digital Resources/Online E-Resources |
20 |
Material Type: Newspaper Article
|
![]() |
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and -Thalassemia StudiesBusiness Wire, 2021-06-07COPYRIGHT 2021 Business Wire, Inc.Digital Resources/Online E-Resources |